MBX — MBX Biosciences Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $33.39
- 30-Day Move
- +17.7%
- Market Cap
- $1.6B
- Shares Outstanding
- 47,510,000
- P/B Ratio
- 3.84
- ROE
- -23.6%
Analyst consensus: Buy · 15 analysts
MBX Biosciences Inc
A read-only Alphactor snapshot forMBX Biosciences Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-23
Topline snapshot
Latest Close
$33.39
30-Day Move
+17.7%
Market Cap
$1.6B
Shares Outstanding
47,510,000
P/B Ratio
3.84
ROE
-23.6%
$33.39
+17.7%last 90 delayed daily bars
90D High
$44.89
90D Low
$26.14
Avg Volume
629,165
MBX is up 17.7% over the last 30 trading days shown on this page.
Latest operating income is $-26M, which helps anchor the headline ratios with an actual earnings figure.
Latest Close
$33.39
30-Day Move
+17.7%
Market Cap
$1.6B
Shares Outstanding
47,510,000
P/B Ratio
3.84
ROE
-23.6%
ROA
-22.6%
Debt / Equity
0
Current Ratio
24.62
Latest Revenue
$0
Revenue
$0
Gross Profit
--
Operating Income
$-26M
Net Income
$-22M
Gross Margin
--
Net Margin
--
Current Ratio
24.62
Debt / Equity
0.00
Altman Z
58.55
Safe
Piotroski
3
Weak (0-3)
Cash Conversion
0.92x
Rule of 40
--
Insufficient data
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $0 | $-25M | $-26M | $-24M |
| 2023-12-31 | $0 | $-35M | $-33M | $-32M |
| 2024-12-31 | $0 | $-68M | $-62M | $-56M |
| 2025-12-31 | $0 | $-98M | $-87M | $-82M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2026-01-29
$57M
+8.4%
Citadel Advisors
Filed 2026-02-17
$26M
--
D.E. Shaw
Filed 2026-02-17
$21M
--
Geode Capital Management
Filed 2026-02-09
$20M
+37.0%
Goldman Sachs
Filed 2026-02-10
$10M
-7.3%
Charles Schwab
Filed 2026-02-13
$7M
+30.7%
Northern Trust
Filed 2026-02-17
$6M
+43.2%
4.13
Consensus
Buy—
—
—
15
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.